CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Aviva Asnis-Alibozek, PA-C, MPAS — Salary: AstraZeneca Pharmaceuticals LP; Shareholder of: AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — Shareholder of: Amgen Inc and Genentech BioOncology. All other Research To Practice staff and external reviewers: No real or apparent conflicts of interest to report.

FACULTY — The following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process: Dr O’Connell — Consulting Fees: ImClone Systems. Dr Marshall — Consulting Fees and Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Amgen Inc, Bristol-Myers Squibb Company, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Meyerhardt — Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Pfizer Inc.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.